Q1 2026 · 13F-HR
Merck & Co., Inc. (MRK)holdings as filed
Filed 2026-05-13 · accession 0000310158-26-000141
$349.4M
Reported value
14
Positions
2026-03-31
Period end
The Brief · Merck & Co., Inc. (MRK) · Q1 2026
AI · grounded in 13F
Merck & Co., Inc. (MRK) established a new position in EIKON THERAPEUTICS INC EIKN worth $17.6M. The fund also opened a new stake in AKTIS ONCOLOGY INC AKTS for $17.0M and increased its holding in TUHURA BIOSCIENCES HURA by 39.39%. Additionally, the fund added XILIO THERAPEUTICS INC XLO as a new position with a $891,309 investment.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 60770K107 | MRNA | MODERNA INC | $117.3M | 33.6% | 2,308,190 | Common | SHARED |
| 71535D106 | PSNL | PERSONALIS INC | $89.5M | 25.6% | 14,044,943 | Common | SHARED |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $64.3M | 18.4% | 772,165 | Common | SHARED |
| 29384C908 | TRDA | ENTRADA THERAPEUTICS INC | $22.0M | 6.28% | 1,739,768 | Common | SHARED |
| 282564103 | EIKN | EIKON THERAPEUTICS INC | $17.6M | 5.05% | 1,666,666 | Common | SHARED |
| 01021M104 | AKTS | AKTIS ONCOLOGY INC | $17.0M | 4.88% | 952,844 | Common | SHARED |
| 014442107 | ALEC | ALECTOR INC | $7.6M | 2.18% | 3,545,719 | Common | SHARED |
| 869367102 | STRO | SUTRO BIOPHARMA INC | $6.8M | 1.94% | 272,351 | Common | SHARED |
| 29970R204 | EVAXUSD | EVAXION BIOTECH A/S | $4.5M | 1.29% | 1,214,126 | Common | SHARED |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $1.8M | 0.52% | 93,414 | Common | SHARED |
| 98422T209 | XLO | XILIO THERAPEUTICS INC | $891,309 | 0.26% | 105,982 | Common | SHARED |
| 14216R101 | CARM | CARISMA THERAPEUTICS INC | $47,880 | 0.01% | 1,473,240 | Common | SHARED |
| 64136E102 | NEUP | NEUPHORIA THERAPEUTICS INC | $40,810 | 0.01% | 10,027 | Common | SHARED |
| 898920103 | HURA | TUHURA BIOSCIENCES | $34,807 | 0.01% | 19,445 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.